Loading...
XNAS
IRTC
Market cap4.12bUSD
Jul 10, Last price  
116.13USD
1D
-5.92%
1Q
2.32%
Jan 2017
293.05%
IPO
357.21%
Name

iRhythm Technologies Inc

Chart & Performance

D1W1MN
XNAS:IRTC chart
P/E
—
P/S
5.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.89%
Rev. gr., 5y
23.02%
Revenues
747m
+26.24%
15,368,00021,749,00036,140,00064,072,00099,129,000147,277,000214,552,000265,166,000322,825,000410,921,000492,681,000591,839,000747,138,000
Net income
-45m
L-60.67%
-13,589,000-15,832,000-22,799,000-20,903,000-29,740,000-50,378,000-54,568,000-43,830,000-101,361,000-116,155,000-123,406,000-113,289,000-44,551,000
CFO
81m
+2,285.34%
-11,849,000-15,626,000-18,005,000-16,651,000-14,911,000-29,068,000-21,863,000-13,759,000-37,753,000-23,012,000-50,101,0003,390,00080,863,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
URL
https://www.irhythmtech.com/
IPO date
Oct 20, 2016
Employees
1,793
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT